Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48-96 weeks of RETROBIC Study.

Jesús Troya GarcíaGuillermo PousadaRafael MicánCarlos GaleraJosé SanzIgnacio de Los SantosCarlos DueñasNoemí CabelloCristina MartínMaría Josefa GalindoMaría Ángeles GarcinuñoRoberto Pedrero-ToméLuis Buzón Martín

Published in: The Journal of antimicrobial chemotherapy (2024)

In long-term virologically controlled PLWH, B/F/TAF achieved high efficacy rates and slightly improved immune status in women and individuals aged 60 and over after 48 and 96 of switching.

Keyphrases

hiv infected
hiv infected patients
antiretroviral therapy
polycystic ovary syndrome
electronic health record
big data
machine learning
metabolic syndrome
pregnancy outcomes
gestational age
insulin resistance
artificial intelligence
breast cancer risk